Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

1. Paz-Ares, L.G.
2. Pérol, M.
3. Ciuleanu, T.-E.
4. Kowalyszyn, R.D.
5. Reck, M.
6. Lewanski, C.R.
7. Syrigos, K.
8. Arrieta, O.
9. Prabhash, K.
10. Park, K.
11. Pikiel, J.
12. Göksel, T.
13. Lee, P.
14. Zimmermann, A.
15. Carter, G.C.
16. Alexandris, E.
17. Garon, E.B.